Half-Sandwich Ru(II) Complexes for Anticancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current platinum-based cancer therapies, such as cisplatin, face challenges including the development of platinum resistance in tumors and adverse side effects, while ruthenium complexes offer promising alternatives with reduced toxicity but require further optimization for enhanced anticancer efficacy.
Innovation Solution
Development of half-sandwich type Ru(II)-arene/arenyl complexes incorporating C- and N-glycopyranosyl azoles as bidentate chelators, which modulate the biological effects by tuning the metal chelating part, basicity, and lipophilic/hydrophilic character of the complex.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If platinum-based complexes (e.g., cisplatin) are used for cancer therapy, then anticancer activity is achieved, but platinum resistance develops in tumors and adverse side effects occur
Solution Approach 1:
The patent changes the metal center from platinum to ruthenium, fundamentally altering the chemical parameters of the complex. This substitution maintains anticancer activity while avoiding platinum resistance mechanisms and reducing toxicity, as ruthenium complexes do not undergo the same resistance development pathways as platinum complexes
Solution Approach 2:
The patent creates composite ruthenium complexes combining multiple ligand types (cyclopentadienyl, glycopyranosyl, azole, carboxylic acid) to achieve synergistic effects. The composite structure provides both anticancer activity and antimicrobial properties, while the specific ligand combination stabilizes the ruthenium center and optimizes biological interactions
2Object-affected harmful factors
If ruthenium complexes are used as alternatives to platinum, then toxicity is reduced, but anticancer efficacy requires further optimization
Solution Approach 1:
The patent introduces a glycopyranosyl ligand with specific local chemical properties (hydroxyl groups, anomeric configuration) that create localized interactions with biological targets. The alpha- or beta-anomeric configuration provides different local binding characteristics that optimize anticancer efficacy while maintaining low toxicity
Solution Approach 2:
The patent employs labile ligands that can dynamically exchange with biological molecules in the tumor microenvironment. The ruthenium complex can adapt its coordination sphere through ligand exchange reactions, enhancing its ability to interact with DNA and other targets while maintaining low toxicity profile
3Ease of operation
If carbohydrate-containing ligands are incorporated into metal complexes, then solubility and cellular uptake are improved, but complex structure and synthesis complexity increase
Solution Approach 1:
The patent divides the ligand system into distinct functional modules: the glycopyranosyl unit providing solubility and cellular recognition, the azole ligand providing coordination chemistry, and the cyclopentadienyl fragment providing structural stability. This segmentation allows independent optimization of each function while simplifying the overall synthesis strategy
Solution Approach 2:
The patent uses the glycopyranosyl-azole linkage as an intermediary structure that bridges the carbohydrate moiety and the metal coordination sphere. This intermediary design facilitates the connection between the hydrophilic sugar unit and the metal center, enabling both improved solubility and stable coordination without excessive structural complexity
Data Source
AI summary
The invention relates to half-sandwich transition metal complexes and uses thereof, in particular in neo-plastic disease or as antifungal agent